{"filings":[{"id":1140716,"accession_number":"0001193125-26-276093","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2026-06-18T21:13:03+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Faeth Therapeutics enters $150M ATM equity facility; Series B preferred converts to common","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Sales Agreement with TD Securities for at-the-market offering of common stock up to $150M.","Agent TD Securities receives up to 3% commission; shares sold at market prices from time to time.","Series B Non-Voting Convertible Preferred (24,435.6 shares) automatically converted into 24,435,594 common shares on June 15.","Post-conversion, common shares outstanding increase to 25,778,754 as of June 15, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1039116,"accession_number":"0001193125-26-270330","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2026-06-15T12:16:14+00:00","items":["1.02","5.02","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Faeth Therapeutics (fka Sensei) appoints new CEO, CFO; PIKTOR Phase 2 data expected H2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name changed to Faeth Therapeutics; ticker to FTH effective June 16, 2026; Austin HQ.","Anand Parikh appointed Chairman, President & CEO; Brian Stephenson appointed CFO.","Board adds former FDA Commissioner Stephen M. Hahn and Saira Ramasastry.","Series B preferred stock converted; $200M gross proceeds from Feb 2026 private placement.","PIKTOR (oral PI3K/AKT/mTOR inhibitor) Phase 2 topline data in advanced endometrial cancer expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":973276,"accession_number":"0001193125-26-265879","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2026-06-10T20:21:05+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Sensei Biotherapeutics stockholders approve 24x increase in authorized shares to 300M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 12.5M to 300M via charter amendment effective June 10.","Approved 2026 Equity Incentive Plan with initial reserve of 2,671,981 shares plus annual 5% escalator through 2036.","Approved 2026 Employee Stock Purchase Plan with initial reserve of 267,198 shares.","Approved issuance of common stock upon conversion of Series B Convertible Preferred, triggering change of control and >20% issuance.","Stockholders elected directors Bob Holmen and Kristian Humer and ratified Deloitte as auditor for FY2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":609160,"accession_number":"0001193125-26-236820","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2026-05-22T20:01:45+00:00","items":["8.01"],"status":"ready","headline":"Sensei Biotherapeutics delays Karen Vousden board appointment to later 2026; board size set to five","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Karen Vousden delays board appointment to later 2026 due to personal reasons; Board to consider appointment in Q3 or Q4 2026.","If stockholder matters pass at June 10 annual meeting, Bob Holmen to become chair of Nominating and Corporate Governance Committee on June 12.","Board size approved at five directors effective upon reconstitution.","Annual meeting scheduled June 10, 2026; definitive proxy filed April 27."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":584196,"accession_number":"0001193125-26-234882","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2026-05-21T21:12:40+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sensei Biotherapeutics schedules June 10 vote on Series B conversion that would trigger change of control","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting on June 10, 2026 to vote on conversion of Series B Preferred Stock into common stock.","Conversion would issue ~24.4M shares, representing >20% of outstanding and result in change of control per Nasdaq rules.","Pro forma shows reclassification of $321.9M from preferred stock to equity; net loss per share improves from $131.45 to $6.62.","Conversion contingent on stockholder approval; if approved, occurs three business days after vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":452517,"accession_number":"0001193125-26-225323","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2026-05-15T11:35:06+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensei Biotherapeutics Q1 net loss $170.2M; cash $202.8M; PIKTOR trial advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $170.2M ($131.45 per share) vs $6.9M loss a year ago, driven by $133.0M acquired IPR&D charge from Faeth acquisition.","Cash, cash equivalents and marketable securities $202.8M, up from $21.2M at Dec 31, 2025, after $200M private placement in February.","First patient dosed in Phase 1b/2 trial of PIKTOR for HR+/HER2- advanced breast cancer; Phase 2 endometrial cancer topline data expected H2 2026.","R&D expenses $18.0M (vs $3.7M) and G&A $19.7M (vs $3.5M) both increased due to Faeth acquisition and one-time costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95954,"accession_number":"0001193125-26-158951","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Three Sensei directors to resign, new CEO & CFO conditional on stockholder approval","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Gerry, Thomas Ricks, Kristian Humer resigning conditionally effective after June 10, 2026 annual meeting, contingent on stockholder approval of Conversion and Charter Amendment Proposals.","Conditional appointments of Stephen Hahn, Saira Ramasastry, Karen Vousden as new directors effective at same time.","If proposals approved, Anand Parikh (current COO) will become CEO; Brian Stephenson will become CFO. Gerry remains General Counsel, Craver remains SVP Finance.","Board adopted Severance and Change in Control Plan covering Parikh, Gerry, Craver with cash severance up to 18 months base salary and COBRA.","Conversion Proposal involves issuance of >20% of common upon Series B preferred conversion, resulting in change of control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95953,"accession_number":"0001193125-26-157038","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K/A","filed_at":"2026-04-15T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Sensei Biotherapeutics files audited Faeth financials; net loss $16M in 2025, going-concern doubt","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Faeth net loss $16.0M in 2025 ($18.3M in 2024); accumulated deficit $77.7M at Dec 31, 2025.","R&D expenses $12.0M (2025) vs $14.1M (2024); cash & equivalents $20.4M at Dec 31, 2025.","Auditor cites substantial doubt about going concern due to potential cash payments from $200M PIPE Series B preferred.","Acquisition of Faeth closed Feb 17, 2026; concurrent $200M PIPE closed Feb 20, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109417,"accession_number":"0001193125-26-130419","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensei Biotherapeutics FY2025 net loss $21.1M; advances PIKTOR with $200M private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $21.1M, or $(16.72) per share, compared to $30.2M loss in prior year.","Cash and marketable securities $21.2M at Dec 31, 2025, down from $41.3M at Dec 31, 2024.","Completed acquisition of Faeth Therapeutics; adds oral PIKTOR candidate targeting PI3K/AKT/mTOR.","Concurrent $200M private placement supports Phase 2 endometrial and Phase 1b breast cancer trials.","Topline data from Phase 2 endometrial and start of Phase 1b breast cancer expected by year-end 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109416,"accession_number":"0001193125-26-056135","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["1.01","5.03","2.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Sensei Biotherapeutics closes merger with Faeth and $200M PIPE; existing holders diluted to ~4.9%","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Issued ~10,602 Series B Preferred shares (each convertible into 1,000 common) to acquire Faeth; pre-PIPE: Faeth holders ~89.3%, Sensei ~10.7%.","Sold 14,440 Series B Preferred shares in $200M PIPE; post-PIPE: PIPE investors ~54.3%, Faeth ~40.8%, Sensei ~4.9%.","Anand Parikh (ex-Faeth CEO) appointed as COO and director; granted 1,239,305 option inducement award vesting over 4 years.","Certificate of Designation filed; conversion of Series B requires stockholder approval and beneficial ownership limits of 4.99%-19.99%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109415,"accession_number":"0001193125-26-051815","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sensei Biotherapeutics appoints two new directors, expanding board to five","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 3 to 5 members; Christopher W. Gerry (President & GC) and Phillip B. Donenberg appointed Feb 13, 2026.","Gerry already serves as President and General Counsel of the company.","Donenberg brings CFO and audit committee experience from Taysha, Tectonic, Jaguar Gene Therapy, and AveXis.","Donenberg will receive non-employee director compensation per 2025 proxy statement.","Each appointee entered standard indemnification agreement with the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125894,"accession_number":"0001193125-25-331113","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sensei Bio sets CEO salary at $425K, SVP at $400K; retention bonuses tied to Feb 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Annual base salaries: Christopher Gerry $425,000, Josiah Craver $400,000, effective Nov 14, 2025.","Each eligible for target annual bonus equal to 40% of base salary beginning FY 2026.","First retention bonus equals full 2025 target bonus if employed through Feb 13, 2026 or terminated without cause.","Second retention bonus is prorated 2026 target bonus if terminated without cause before 2026 bonus payment; 2x multiplier if not change-in-control.","Severance benefits require execution of separation agreement and release of claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125893,"accession_number":"0001193125-25-281581","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensei discontinues solnerstotug, starts strategic review; workforce cut 65%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinued solnerstotug development; Board considering sale, merger, or wind-down.","Workforce cut ~65% to preserve cash; small team retained for strategic review.","Cash $25.0M as of Sep 30, 2025, down from $41.3M at Dec 31, 2024.","Q3 2025 net loss $4.6M (vs $7.3M YoY); R&D $2.5M (vs $4.6M YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125892,"accession_number":"0001193125-25-257621","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sensei Biotherapeutics discontinues solnerstotug, initiates strategic review for sale or wind-down","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board discontinues development of solnerstotug after review of pipeline and market conditions.","Initiated comprehensive review of strategic alternatives, including sale, merger, licensing, or orderly wind-down.","Workforce reduction planned to preserve cash; details to be disclosed separately.","Small team retained to assist with strategic review, regulatory compliance, and orderly cessation of development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125891,"accession_number":"0001193125-25-242007","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sensei Biotherapeutics reports 50% 6-month PFS for solnerstotug in PD-(L)1 resistant tumors at ESMO 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["6-month PFS of 50% in 15 mg/kg dose cohort in PD-(L)1 resistant patients vs historical ~10-20% for docetaxel.","Complete response in Merkel cell carcinoma patient; duration of response 54+ weeks. Four of six responders had late onset responses (18-54 weeks).","Favorable safety: only six mild Grade 1 CRS events across all 98 patients; no new safety signals.","Phase 2 studies planned in 2L NSCLC and Merkel cell carcinoma in 2026, subject to FDA feedback and capital raise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142655,"accession_number":"0001193125-25-173043","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensei Biotherapeutics Q2 net loss $4.9M; cash runway into Q2 2026; Phase 1/2 data year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $28.6M at June 30, 2025 (down from $41.3M at Dec 31, 2024).","Net loss $4.9M for Q2 2025 vs $7.1M for Q2 2024; R&D expenses decreased to $2.5M from $4.6M.","Phase 1/2 dose expansion cohort enrollment complete (64 patients); full data including 6-month PFS expected by year-end 2025.","Data to be presented at ESMO Congress 2025 (Oct 17-21) in a mini oral session.","Regained Nasdaq compliance after 1-for-20 reverse split effective June 16, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-9.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142654,"accession_number":"0001193125-25-157113","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Sensei Biotherapeutics regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on July 2, 2025 confirming compliance with Rule 5550(a)(2).","Closing bid price was at or above $1.00 for 10 consecutive business days (June 17 to July 1, 2025).","No further action required; delisting risk removed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160704,"accession_number":"0001193125-25-140329","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Sensei Biotherapeutics announces 1-for-20 reverse stock split effective June 16","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-20 ratio effective 5:00 p.m. ET on June 16, 2025.","Authorized shares reduced from 250,000,000 to 12,500,000; par value unchanged.","No fractional shares issued; stockholders receive cash payment in lieu.","Common stock trades on split-adjusted basis on Nasdaq Capital Market starting June 17, 2025.","Outstanding stock options, RSUs, and warrants proportionately adjusted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160703,"accession_number":"0001193125-25-125484","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sensei Biotherapeutics shareholders approve reverse stock split at 1:10-1:30 ratio","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected directors William Ringo (8.9M for) and John Celebi (9.2M for) to three-year terms.","Ratified Deloitte & Touche as independent auditor for FY2025: 15.8M for, 369.9K against.","Approved reverse stock split authorization (ratio 1:10 to 1:30) at board discretion; 14.7M for, 1.6M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160702,"accession_number":"0001193125-25-113299","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensei Biotherapeutics Reports Q1 2025 Results; Clinical Progress for Solnerstotug in PD-(L)1 Resistant Tumors","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.9 million for Q1 2025, down from $8.0 million in Q1 2024.","Cash, cash equivalents and marketable securities were $34.3 million as of March 31, 2025, expected to fund operations into Q2 2026.","Dose expansion enrollment complete with 63 patients; full Phase 1/2 data expected by year-end 2025.","Favorable clinical activity observed in PD-(L)1 resistant 'hot' tumors, with response rates nearly three times higher than typical rechallenge."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178911,"accession_number":"0001193125-25-066261","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensei Bio reports Q4 2024 cash of $41.3M; Phase 1/2 solnerstotug data shows 14% ORR in PD-(L)1 resistant tumors","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Phase 1/2 dose expansion data: 14% ORR (3x historical PD-(L)1 rechallenge rates) and 62% DCR in PD-(L)1 resistant hot tumors; one complete response in Merkel cell carcinoma.","Target enrollment of 60 patients achieved in dose expansion cohort; full data expected by year-end 2025.","Net loss $30.2M for FY2024 (vs $34.1M FY2023); cash, equivalents and marketable securities $41.3M as of Dec 31, 2024, with runway into Q2 2026.","Solnerstotug well-tolerated: no dose-limiting toxicities; majority of adverse events Grade 1-2; 7% Grade 1 cytokine release syndrome.","Corporate updates: Q4 restructuring, appointment of Josiah Craver as Principal Financial Officer, and Dr. Ron Weitzman as part-time CMO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178910,"accession_number":"0001193125-25-065634","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sensei reports solnerstotug 14% ORR in PD-(L)1 resistant tumors; Phase 2 planned Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["14% ORR (3/21 evaluable) and 62% DCR in PD-(L)1 resistant 'hot' tumors; nearly 3x historical rechallenge response.","One durable CR in Merkel Cell Carcinoma (42+ weeks) and two PRs (MCC and MSI-H CRC, 12+ and 36+ weeks).","All patients with tumor shrinkage remain on study, suggesting potential for deepening responses.","Solnerstotug well tolerated: no DLTs; mild CRS in 4/60 patients (Grade 1 only).","Phase 2 initiation expected Q1 2026, subject to sufficient capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178909,"accession_number":"0001193125-25-002920","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Sensei Biotherapeutics gets bid-price extension to July 7, 2025; transfers to Nasdaq Capital Market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq approved transfer to Capital Market; trading under SNSE starts Jan 8, 2025.","Received additional 180-day period until July 7, 2025 to regain $1 minimum bid compliance.","If not compliant by July 7, Nasdaq will issue delisting notice; company may appeal but no guarantee.","Evaluating options including reverse stock split to address bid price deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195585,"accession_number":"0001193125-24-258006","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensei Biotherapeutics cuts workforce 46%, extends cash runway into Q2 2026; Q3 net loss $7.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.3M for Q3 2024 vs $7.1M year ago; cash & securities $47.0M as of Sept 30.","Organizational restructuring: closing Rockville research site, reducing workforce ~46%, focusing on SNS-101.","SNS-101 Phase 1/2 dose expansion clinical data expected in H1 2025; enrollment ~50% complete.","Appointed Josiah Craver as SVP Finance, principal financial and accounting officer in September."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195584,"accession_number":"0001193125-24-247599","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Deneen Vojta resigns from Sensei Biotherapeutics board, effective Dec 31, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Deneen Vojta, MD notified the Board of her resignation on October 25, 2024.","Resignation effective December 31, 2024; cited personal reasons, no disagreement with Company.","No replacement announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211843,"accession_number":"0001193125-24-222937","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sensei Biotherapeutics appoints Josiah Craver as principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Craver appointed principal financial and accounting officer effective Sept 17, 2024; previously SVP Finance since July 2024.","Base salary $360,000, annual bonus target 35%, and stock option for 80,000 shares vesting over 4 years.","Severance: six months salary if terminated without cause/good reason; 12 months salary plus bonus and equity acceleration upon change in control.","David Gaiero ceased serving as interim principal financial and accounting officer immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211842,"accession_number":"0001193125-24-194428","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensei Biotherapeutics Q2 net loss $7.1M; cash $52.3M; SNS-101 dose expansion on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.1M vs $9.4M in Q2 2023; R&D $4.6M (-$0.2M), G&A $3.2M (-$2.2M).","Cash $52.3M, expected to fund operations into Q4 2025.","Phase 1/2 SNS-101 dose expansion enrollment advancing; initial data Q4 2024; end-of-Phase 1 FDA meeting by year-end.","ASCO 2024 data showed well-tolerated safety, best-in-class PK, and early clinical activity.","Appointed Josiah Craver as SVP of Finance, effective July 22, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211841,"accession_number":"0001193125-24-178607","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Sensei Biotherapeutics receives Nasdaq bid-price deficiency notice; 180 days to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Sensei on July 10, 2024 that common stock closed below $1.00 for 30 consecutive business days.","Company has until January 6, 2025 to regain compliance by closing at $1.00 or more for at least 10 consecutive days.","If not cured, may transfer to Nasdaq Capital Market with $5,000 fee and meet other listing standards.","Options to cure include potential reverse stock split; no assurance of maintaining listing.","Notice has no immediate impact on trading; Company will monitor and consider available remedies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230627,"accession_number":"0001193125-24-170690","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Jessie English resigns from Sensei Biotherapeutics board effective July 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jessie English, PhD notified Board of resignation on June 26, 2024, effective July 1, 2024.","Resignation due to personal reasons; no disagreement with Company's operations, policies, or practices.","No replacement named; Board size reduced to current members."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230626,"accession_number":"0001193125-24-160769","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sensei Biotherapeutics stockholders reelect all three director nominees at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected directors Jessie English, James Peyer, Thomas Ricks; each received ~9-10M votes for, ~0.8-1.9M withheld.","Ratified Deloitte & Touche as independent auditor for FY 2024 with 16.3M for, 0.8M against, 17k abstentions.","Approximately 68.2% of outstanding shares (17.1M of 25.1M) were present or represented at the meeting.","Broker non-votes on director election totaled ~6.1M for each nominee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230625,"accession_number":"0001193125-24-152363","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sensei Biotherapeutics updates corporate presentation for investor meetings","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed an updated corporate presentation on June 3, 2024 under Regulation FD.","Presentation used in meetings with investors but no specific new data disclosed.","No financial results, pipeline updates, or clinical milestones included in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230624,"accession_number":"0001193125-24-146093","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sensei Biotherapeutics reports Phase 1 data for SNS-101: 59% tumor reduction in MSS endometrial cancer, well tolerated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Confirmed partial response (59% decrease) in an MSS endometrial cancer patient on SNS-101 plus cemiplimab; remains on study at 30+ weeks.","No dose-limiting toxicities; most AEs grade 1-2; mild cytokine release syndrome at highest dose manageable.","PK profile shows linear elimination and dose-proportional exposure, supporting once-every-3-week dosing.","Tumor regression observed in MSS CRC (27%), pembrolizumab-resistant RCC (18%), and HPV+ head & neck cancer (17%).","Company expects initial dose expansion data and end-of-Phase 1 FDA meeting by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230623,"accession_number":"0001193125-24-134767","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensei Biotherapeutics Q1 net loss narrows to $8M; SNS-101 Phase 1 dose escalation complete, no DLTs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.0M for Q1 2024 vs $10.2M in Q1 2023; R&D spend $4.9M, G&A $3.8M.","Cash, cash equivalents and marketable securities $58.1M at March 31, 2024; runway into Q4 2025.","SNS-101 Phase 1/2 dose escalation completed: 16 patients monotherapy, 18 combination; no DLTs observed.","Topline data at ASCO 2024; dose expansion enrolling; end-of-Phase 1 FDA meeting expected by end of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230622,"accession_number":"0001193125-24-094756","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2024-04-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sensei Bio enters consulting agreement with former CFO Erin Colgan for transition through April 30, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Erin Colgan, former CFO, will provide transition services through April 30, 2024 under a consulting agreement.","Consulting fee of $1,640 per business day.","Exercise period for her existing vested stock options extended to October 7, 2024 or later per plan/award.","Agreement expires automatically on April 30, 2024 unless terminated earlier."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230621,"accession_number":"0001193125-24-084096","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sensei Biotherapeutics CFO Erin Colgan resigns effective April 10, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Erin Colgan resigns as CFO and all positions, effective April 10, 2024.","Resignation is voluntary and not due to any disagreement with the company.","No successor has been announced; transition details are not provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249007,"accession_number":"0001193125-24-059356","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["1.01","3.03","9.01"],"status":"ready","headline":"Sensei Biotherapeutics extends stockholder rights plan to March 2025, removes 'acting in concert' definition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second Amendment to Rights Agreement extends expiration date to March 7, 2025 (from March 7, 2024).","The amendment eliminates the 'acting in concert' beneficial ownership provision from the Rights Agreement.","Rights remain subject to earlier redemption, exchange, or termination per the agreement.","Amendment is between Sensei Biotherapeutics and Equiniti Trust Company, LLC, as Rights Agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249006,"accession_number":"0001193125-24-049197","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensei Biotherapeutics FY 2023 net loss $34.1M; cash into Q4 2025; SNS-101 data due Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $34.1M in FY2023 vs $48.6M in FY2022; R&D expense fell to $18.3M from $30.4M.","Cash, equivalents, and marketable securities $65.8M at Dec 31, 2023 (down from $107.1M); runway now into Q4 2025.","SNS-101 Phase 1/2: topline efficacy/biomarker data expected Q2 2024 (ahead of prior guidance); no DLTs in 33 patients.","Resource realignment: paused preclinical TMAb programs (SNS-102, SNS-103, SNS-201) to focus on SNS-101.","Appointed Ron Weitzman as part-time CMO (Jan 2024) and Stephanie Krebs as CBO (Nov 2023)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249005,"accession_number":"0001193125-24-028396","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Director Samuel Broder resigns from Sensei Biotherapeutics board; board reduced to eight","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Samuel Broder, MD resigned from the Board effective February 5, 2024, not due to any disagreement with the Company.","Dr. Broder will remain as a consultant providing strategic guidance on science, clinical development, and regulatory pathways.","Board reduced from nine to eight directors effective February 6, 2024.","Bill Ringo appointed as Interim Chair of the Nominating and Corporate Governance Committee, effective immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249004,"accession_number":"0001193125-24-001950","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sensei Biotherapeutics updates corporate deck; no specific new info in excerpt","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Exhibit 99.1 includes only title slide and disclaimer; full presentation not provided.","No financial results, pipeline updates, or guidance changes are detailed in the excerpt.","Company uses presentation for investor meetings; no material event announced.","Confidence low due to incomplete exhibit text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266538,"accession_number":"0001193125-23-271921","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensei Biotherapeutics Q3 net loss $7.1M; cash $72M; SNS-101 Phase 1 data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.1M in Q3 2023 vs $13.4M in Q3 2022; cash $72.0M as of Sept 30, 2023, down from $107.1M at Dec 31, 2022.","R&D expenses $3.8M vs $9.2M YoY; G&A $3.9M vs $4.8M; cash runway expected into H2 2025.","SNS-101 Phase 1 data at SITC: no cytokine release syndrome, no dose-limiting toxicities, dose-proportional pharmacokinetics.","Enrollment ahead of schedule: 17 patients treated; monotherapy dose escalation at 15 mg/kg; combination arm cleared 3 mg/kg.","Apped Stephanie Krebs as CBO; SNS-201 and SNS-102 lead candidates selected; milestones: combo data Q1 2024, monotherapy topline Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266537,"accession_number":"0001193125-23-270798","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Sensei Biotherapeutics board unanimously rejects Newtyn's $1.00/share takeover bid","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Received unsolicited proposal from Newtyn Management to acquire all shares at $1.00/share in cash.","Board unanimously determined proposal substantially undervalues the company and its future prospects.","Company believes it is well-positioned to execute strategy and create long-term value for stockholders.","Rejection formalized on November 6, 2023; no further terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266536,"accession_number":"0001193125-23-270377","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sensei Biotherapeutics reports favorable Phase 1/2 data for SNS-101 at SITC 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SNS-101 dose escalation (13 patients): well-tolerated, no DLTs, no CRS; only one related AE (Grade 2 dermatitis).","Pharmacokinetics: dose-proportional exposure, linear elimination, no target-mediated drug disposition; supports every-three-week dosing.","SNS-101 achieved dose levels >10x higher than a competitor VISTA antibody that was halted due to CRS, suggesting best-in-class potential.","Expected data readouts: initial combo safety/PK data Q1 2024, topline monotherapy Q2 2024, topline combo later in 2024.","Late-breaking poster at SITC 2023 on Nov 4; data supports conditionally active VISTA-blocking approach."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266535,"accession_number":"0001193125-23-259994","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2023-10-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Sensei Biotherapeutics receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Sensei on Oct 17, 2023 that stock bid price <$1 for 30 consecutive days, violating Listing Rule 5450(a)(1).","Company has 180 days (until April 15, 2024) to regain compliance by closing at $1.00+ for 10 consecutive business days.","Options include transferring to Nasdaq Capital Market or effecting a reverse stock split; company will monitor and consider remedies.","If not cured within compliance periods, Nasdaq will delist shares; company may appeal to a Hearings Panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283771,"accession_number":"0001193125-23-202349","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensei Biotherapeutics Q2 2023 net loss $9.4M; SNS-101 Phase 1/2 enrolling 6 patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $78.8M at June 30, 2023, down from $107.1M at Dec 31, 2022; cash runway into H2 2025.","Net loss $9.4M vs $10.5M YoY; R&D expenses $4.8M (down from $6.4M) due to restructuring and lower manufacturing costs.","G&A expenses $5.4M included $1.56M non-recurring stockholder activism costs related to the 2023 annual meeting.","SNS-101 Phase 1/2 enrolled 6 patients across 3 cohorts; combination arm with Libtayo (cemiplimab) expected Q4 2023; PK/safety data by year-end 2023.","Robert Schreiber appointed Chair of Immuno-Oncology Advisory Board; SNS-102 and SNS-103 lead optimization completed, candidate selection expected in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283770,"accession_number":"0001193125-23-184650","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2023-07-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sensei Biotherapeutics reports annual meeting results; all director nominees elected, Deloitte ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Bob Holmen elected with 12,245,867 votes for, 2,181,612 withheld.","Kristian Humer elected with 11,914,421 votes for, 2,513,058 withheld.","Deneen Vojta elected with 11,503,426 votes for, 2,924,053 withheld.","Broker non-votes of 2,117,571 on each director proposal.","Ratification of Deloitte & Touche as auditor passed with 16,096,264 for, 571 against, 448,215 abstained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303328,"accession_number":"0001193125-23-175647","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2023-06-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sensei Biotherapeutics hosts SNS-101 KOL event; no new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Virtual key opinion leader event on June 27, 2023, featuring SNS-101 for solid tumors.","Presenters include CEO John Celebi, CSO Dr. Edward van der Horst, CMO Ron Weitzman.","Guest speaker: Dr. James Gulley, Co-Director, Center for Immuno-Oncology at NCI.","Event is forward-looking; no clinical results or financial guidance provided.","SNS-101 positioned as potential transformative treatment; no material milestones announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303327,"accession_number":"0001193125-23-173860","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["1.01","3.03","9.01"],"status":"ready","headline":"Sensei Biotherapeutics amends Rights Agreement to remove obsolete references to former stockholders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to Rights Agreement dated June 23, 2023 removes language about Apeiron Parties who no longer hold shares.","No material change to rights of security holders; cleanup of obsolete provisions.","Apeiron Parties sold all shares per Purchase Agreement dated May 23, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303326,"accession_number":"0001193125-23-151834","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2023-05-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Sensei Biotherapeutics repurchases 4.45M shares from Apeiron at $1.58/sh, ends proxy contest","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company to buy 4,454,248 shares from Apeiron Parties at $1.58/share, eliminating their entire beneficial ownership.","Apeiron withdraws its March 2023 notice to nominate three directors for the 2023 annual meeting.","Share repurchase does not change previously disclosed cash runway into second half of 2025.","Standstill and voting agreement applies through the earlier of 4 years or 30 days before 2027 annual meeting.","Company plans to initiate Phase 1/2 clinical trial of lead candidate SNS-101 in mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303325,"accession_number":"0001193125-23-138934","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sensei Biotherapeutics reports Q1 2023 net loss of $10.2M; IND cleared for SNS-101 Phase 1/2 trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities were $95.5M as of March 31, 2023; cash runway into H2 2025.","Net loss was $10.2M for Q1 2023, compared to $12.4M for Q1 2022; R&D expenses decreased to $5.2M.","FDA cleared IND for SNS-101 (conditionally active anti-VISTA antibody); Phase 1/2 trial enrollment and dosing expected mid-2023.","CRADA signed with NCI for VISTA research; SNS-102 and SNS-103 candidate selection on track for 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303324,"accession_number":"0001193125-23-107449","cik":1829802,"company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","form_type":"8-K","filed_at":"2023-04-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Sensei Biotherapeutics updates corporate presentation for investor meetings","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation dated April 2023 furnished as Exhibit 99.1.","No specific clinical, financial, or operational updates disclosed in filing.","Presentation used for meetings with investors, analysts, and others.","Information furnished under Regulation FD, not deemed filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":22745899.288288288,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-04-20T23:59:59+00:00|303324"}